Nivalis Therapeutics (NVLS) Stock: Here’s What You Need To Know

Nivalis Therapeutics (NASDAQ:NVLS) On Monday Nivalis Therapeutics stock fell by more than 52% after the company announced that it had failed its phase 2 trial in patients with Cystic Fibrosis — CF. As soon as the results were released the stock tumbled as investors sold their shares to the open market. The phase 2 trial … Read more